Drug Profile

HP 568

Alternative Names: HP-568

Latest Information Update: 21 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hinova pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action Estrogen receptor degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I/II HER2 negative breast cancer

Most Recent Events

21 Apr 2026 Phase-I clinical trials in HER2-negative-breast-cancer in USA (PO) prior to April 2026 (Hinova Pharmaceuticals pipeline; April 2026)
17 Apr 2026 The US FDA approves IND application for HP 568 for HER2-negative-breast-cancer
25 Apr 2025 Pharmacodynamics and adverse events data preclinical studies in Breast cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com